Rights issue in Oncopeptides AB (SE) — SEK 314 million Healthcare Rights issue in Oncopeptides AB (SE) — SEK 314 million
Private placement in Turbotic AB (SE) – SEK 26 million TMT Private placement in Turbotic AB (SE) – SEK 26 million
Directed new share issue in Hansa Biopharma AB (SE) — SEK 372 million Healthcare Directed new share issue in Hansa Biopharma AB (SE) — SEK 372 million
Senior secured bonds by Francks Kylindustri Holding AB (SE) – SEK 550 million Business Services Senior secured bonds by Francks Kylindustri Holding AB (SE) – SEK 550 million
Directed new share issue in Ferroamp AB (SE) — SEK 39 million Cleantech, Renewables & Infrastructure Directed new share issue in Ferroamp AB (SE) — SEK 39 million
Extension of credit facilities and Rights issue in Nobia AB (SE) — SEK 1,262 million Consumer & Retail Extension of credit facilities and Rights issue in Nobia AB (SE) — SEK 1,262 million
Divestment of selected assets from Saber Interactive Inc. (US) by Embracer Group AB (SE) — SEK 2,527 million TMT Divestment of selected assets from Saber Interactive Inc. (US) by Embracer Group AB (SE) — SEK 2,527 million
Rights issue in Vimian AB (SE) — SEK 1,633 million Healthcare Rights issue in Vimian AB (SE) — SEK 1,633 million
Rights issue in Acconeer AB (SE) — SEK 149 million TMT Rights issue in Acconeer AB (SE) — SEK 149 million
Directed share issue in Smart Eye AB (SE) – SEK 150 million TMT Directed share issue in Smart Eye AB (SE) – SEK 150 million
Recommended public cash offer to the shareholders of Awardit AB — SEK 1,143 million TMT Recommended public cash offer to the shareholders of Awardit AB — SEK 1,143 million
Senior secured social bonds by Orexo AB (SE) – SEK 500 million Healthcare Senior secured social bonds by Orexo AB (SE) – SEK 500 million